Insurance coverage basics for GLP-1 weight-loss care

Updated May 2026 · 6 min read · Educational only, not medical advice

Insurance for weight-loss medications is one of the most confusing parts of the patient experience. The same drug can be fully covered for one person and fully out-of-pocket for another because of policies set at the plan and employer level. This article explains the moving parts so you know what to ask.

Two different drug indications, two different coverage worlds

Most GLP-1s are approved for both type 2 diabetes and chronic weight management, often under different brand names. Insurance often covers them generously for diabetes and inconsistently — or not at all — for weight loss.

This means the same active ingredient may be:

• Covered with a low copay if you have type 2 diabetes
• Not covered at all if your prescription is for weight management
• Covered with a high copay and prior authorization for weight management
• Covered only after step therapy through other medications

Commercial / employer plans

Commercial plans vary widely. Many large employer plans have added or considered "weight-loss medication" exclusions in recent years because of cost. Others have rich coverage with prior authorization. The fastest way to find out is to call your plan and ask:

• Is Wegovy (or Zepbound, or Saxenda) covered under my plan?
• What are the prior authorization criteria?
• What is my expected out-of-pocket cost?
• Are there step-therapy requirements?
• Does coverage require enrollment in a structured lifestyle program?

Medicare

As of 2026, Medicare Part D coverage of GLP-1s specifically for weight loss remains limited. Medicare has historically not covered weight-loss medications across the board. Policy changes are being debated; check current rules with Medicare directly or with a benefits counselor.

Medicaid

Medicaid coverage of GLP-1s for weight loss is set state-by-state. Some states cover under specific criteria; others don't. Call your state's Medicaid managed-care plan to ask.

Prior authorization in detail

Prior authorization (PA) is the insurer's way of confirming the prescription meets their clinical criteria before paying. For GLP-1 weight-loss medications, PAs typically ask for:

• Documented BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition
• Evidence of a documented lifestyle intervention attempt (often 3–6 months)
• Clinical notes on weight-loss goals and counseling provided
• Lab work, sometimes

PAs are usually decided within a few business days for non-urgent requests. If denied, you typically have appeal rights — and providers can write a "letter of medical necessity" supporting the appeal.

Step therapy

Some plans require you to try an older or cheaper medication first before approving a newer one. If you have a clinical reason that step therapy isn't appropriate, your provider can request an exception.

Manufacturer savings programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) run patient-assistance and copay programs. Eligibility varies and changes; in general, these programs help reduce cost for commercial-insured patients and offer some help for self-pay. They generally do not apply to Medicare or Medicaid patients.

When coverage falls through

If you can't get coverage, options include:

• Manufacturer savings programs (if eligible)
• Cash-pay at brand list prices, often around $1,000+/month before discounts
• Compounded GLP-1s through telehealth (cheaper but with safety considerations)
• Pursuing other treatment paths with your clinician

Some employers run separate weight-loss benefit programs that aren't part of regular medical coverage. Worth asking HR.

The Coverage Navigator

WeightWise offers a coverage checklist that walks you through the calls and documents you'll need. Find it in the tools section.